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Dental caries remains one of the most common global chronic diseases caused by Streptococcus mutans, which is prevalent all 
over the world. The caries prevalence of children aged between 5–6 years old in China is still in very high rate. A potent and 
effective anti-caries vaccine has long been expected for caries prevention but no vaccines have been brought to market till now 
mainly due to the low ability to induce and maintain protective antibody in oral fluids. This review will give a brief historical 
retrospect on study of dental caries and pathogenesis, effective targets for anti-caries vaccines, oral immune system and im-
munization against dental caries. Then, salivary IgA antibodies and the protective responses are discussed in the context of the 
ontogeny of mucosal immunity to indigenous oral streptococcal. The methods and advancement for induction of specific anti-    
caries salivary sIgA antibodies and enhancement of specific anti-caries salivary sIgA antibodies by intranasal immunization 
with a safe effective mucosal adjuvant are described. The progress in the enhancement of salivary sIgA antibodies and anti-     
caries protection by intranasal immunization with flagellin-PAc fusion protein will be highlighted. Finally, some of the main 
strategies that have been used for successful mucosal vaccination of caries vaccine are reviewed, followed by discussion of the 
mucosal adjuvant choice for achieving protective immunity at oral mucosal membranes for development of a nasal-spray or 
nasal-drop anti-caries vaccine for human. 
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Dental caries is a chronic, infectious disease that results in 
localized dissolution and destruction of the calcified tissue 
mainly by Streptococcus mutans (S. mutans) [1–3]. This 
disease is one of the most common global chronic diseases 
caused by bacterial infection, which is prevalent in devel-
oped, developing, and underdeveloped countries and is dis-
tributed unevenly among the populations. The disease usu-
ally develops slowly and can occur throughout life, which 
affects children, adolescents, as well as adults. Furthermore, 
it is still a major oral health problem in most industrialized 
countries, affecting 60%–90% of schoolchildren and the 
vast majority of adults. It is also a most prevalent oral dis-
ease in China [4,5]. According to the third national epide-
miological investigation on oral diseases in China conduct-
ed in 2005, the caries prevalence rate of children aged be-
tween 5–6 years old remains as high as 66%, people of 
35–44 and 65–74 years old reach 61% and 75.2% respec-
tively [6]. More than 98% of Chinese elder population has 
root-surface caries. 
Anti-caries vaccine has long been expected for caries 
prevention since the early fifties of the 20th century. Many 
kinds of vaccine immunogens such as protein, recombinant 
or synthetic peptide, protein-carbohydrate conjugate, or 
DNA-based active vaccines and mucosal adjuvants such as 
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heat-labile enterotoxins (HLT) from Vibrio cholera (LT-I) 
or Escherichia coli (LT-II), bupivacaine, chitosan have been 
successful in animal models [7–12]. However, no vaccines 
have been brought to market till now mainly due to the low 
ability to induce and maintain protective antibody in oral 
fluids. New mucosal immunization strategies and safe mu-
cosal adjuvants have drawn attention for safe and effective 
anti-caries vaccine, which is facilitating the development of 
anti-caries vaccine from research bench to clinical use.  
Flagellin as the ligand of toll-like receptor 5 (TLR5) has 
been proven to be an effective mucosal adjuvant and be-
come promising for clinical use [13–19]. We applied the 
recombinant flagellin as mucosal adjuvant in anti-caries 
vaccines by nasal immunization, either using flagellin di-
rectly by simple mixing with antigen or using fusion strate-
gy to combine flagellin and the target antigen in a single 
fusion protein, proved the efficacy for enhancement of spe-
cific IgA response in oral fluids and better protection 
against caries [11,20,21]. Here, I review some of the main 
strategies that have been used for successful mucosal vac-
cination of caries vaccine and discuss the importance of the 
mucosal adjuvant choice for achieving protective immunity 
at oral mucosal membranes. 
1  Dental caries and pathogenesis 
The pathogenesis of caries had been studied for decades.   
S. mutans, Streptococcus sobrinus (S. sobrinus) and their 
relatives, collectively known as the mutans streptococci, 
have been affirmed to be the major causative agents of den-
tal caries in humans [2,3]. Serotype c S. mutans strains are 
most frequently isolated from the human oral cavity [3]. 
These bacteria are usually endogenous in adults and can be 
transferred from mother to child and are present at varying 
levels in all human mouths [22,23]. Both S. mutans and S. 
sobrinus produce water-soluble and water-insoluble glucans 
from sucrose, by the combined action of glucosyltransfer-
ases, which is necessary for the accumulation of bacteria 
cells on the tooth surface. The bacteria adhere and congre-
gate on the surface of tooth, then the metabolized lactate 
lead to decalcification in enamel, followed by damage in 
dentin and dental pulp [24].  
Currently used strategies for caries prevention, such as 
oral health education, chemical and mechanical control of 
plaque, use of fluorides, and application of pit and fissure 
sealants, are mostly broadly effective [25]. However, eco-
nomic, behavioral, or cultural barriers to their use have con-
tinued the epidemic of dental disease in the mouths of many 
people on a global level. Furthermore, currently used strate-
gies for treatment of the disease are largely limited to re-
moval of the diseased part of the tooth and placing a suita-
ble restoration, which is of high cost but not able to eradi-
cate caries on other teeth. Although this disease has attract-
ed increasing attention in recent decades, scant attention is 
paid to controlling the disease itself. Immunization pro-
grams have led to the elimination and/or control of different 
infectious diseases, including smallpox, polio, measles, 
mumps, rubella, Haemophilus influenza type B disease, 
pertussis, tetanus, and diphtheria. Development of an effec-
tive anti-caries vaccine is becoming urgently required as the 
final best way to prevent caries in the future. 
2  Effective targets for anti-caries vaccines 
The very initial studies on dental caries vaccines applied 
whole cells of mutans streptococci as a possible vaccine 
[26,27]. Thereafter, various cell-surface antigens of mutans 
streptococci and their recombinant fragments or even syn-
thetic peptides have been studied as possible candidates for 
dental caries vaccines [28,29]. In the recent decade, atten-
tion has become focused on three protein antigens: the sur-
face fibrillar adhesins, the glucosyltransferases (GTF) and 
the glucan-binding proteins, all of which have demonstrable 
associations with virulence and the process of tooth surface 
colonization [8,12,30–32]. It is demonstrated that the strep-
tococcal surface fibrillar adhesins control attachment to 
tooth surfaces, the glucosyltransferases produce adhesive 
glucans from sucrose, and the cell-wall-associated glu-
can-binding proteins have the ability to bind α-1,6-glucan 
and may provide the receptors for glucan-mediated aggre-
gation [33]. These components can be utilized as effective 
targets for anti-caries vaccines.  
2.1  Adhesins 
The streptococcal surface adhesin proteins as effective an-
tigenic components have been obtained from S. mutans 
(variously identified as antigen I/II, PAc, or P1) and S. so-
brinus (SpaA or PAg). Abundant in vitro and in vivo evi-
dence indicates that antibody with specificity for S. mutans 
PAc or S. sobrinus SpaA can interfere with bacterial adher-
ence and subsequent dental caries [33]. PAc has been uti-
lized in experimental systems and proven to be a most ef-
fective immunogen for caries vaccine development in many 
forms such as in full-length protein, recombinant or syn-
thetic peptide [34], protein-carbohydrate conjugate [35], or 
DNA-based active vaccines [12]. 
2.2  Glucosyltransferases (GTFs) 
S. mutans and S. sobrinus each synthesize several glucosyl-
transferases. The activity of GTF is mediated through both 
catalytic and glucan-binding functions. The presence of 
antibody to glucosyltransferase in the oral cavity prior to 
infection can significantly influence the disease outcome, 
presumably by interference with one or more of the func-
tional activities of the enzyme. The antibody directed to 
native GTF or sequences associated with its catalytic or 
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glucan-binding function interferes with the synthetic activi-
ty of the enzyme and with in vitro plaque formation [33,36]. 
Thus GTF has also been utilized in experimental systems 
and proven to be an effective immunogen for caries vac-
cines. 
2.3  Glucan-binding proteins (GBP) 
At least three S. mutans glucan-binding proteins GbpA, 
GbpB and GbpC were identified to date [37]. Only GbpB, 
which is 431 residues long and has a calculated molecular 
weight of 41.3 kD, has been shown to induce protective 
immune responses to experimental dental caries. 
3  Oral immune system and immunization 
against dental caries  
Components of the oral immune system include the salivary 
glands, along with mucosal secretions, which contain an 
antibody called secretory immunoglobulin A, or “sIgA”, 
which can survive in harsh environments such as digestive 
and respiratory tracts. Secretory IgA protects the entire 
body against a multitude of invading microbes, and is re-
sistant to degradation caused by exposure to various en-
zymes. Due to the salivary secretions, this secretory immu-
noglobulin also coats and protects every tooth and helps 
protect them from harmful bacteria that may cause decay. 
Although sIgA antibody in saliva and other secretions is 
essentially absent at birth, mature sIgA, i.e., dimeric IgA 
with a bound secretory component, is the principal salivary 
immunoglobulin secreted in individuals by one month of 
age [38,39]. Children between 12 and 24 months exhibit a 
broader range of generally higher salivary IgA concentra-
tions (median concentrations of 50–60 g mL1) than seen 
in the 1st year [40]. The concentrations of IgG, IgA, and 
IgM in unstimulated human whole saliva are 14, 194 and 2 
g mL1, respectively, indicating that secretory IgA (sIgA) 
is quantitatively the most important immunoglobulin in sa-
liva [41,42]. Therefore, sIgA is the principal immune com-
ponent of major and minor gland salivary secretions and 
considered to be the primary effector of adaptive immunity 
in the salivary milieu. 
A large body of studies over several decades has demon-
strated the feasibility of inducing protective immunity 
against mutans streptococci and the subsequent develop-
ment of dental caries in animal models. More and more 
mucosal applications of dental caries vaccines have been 
sought. It is demonstrated that the anti-caries activity has 
been attributed to mutans streptococci-specific sIgA anti-
bodies which can inhibit sucrose-independent or sucrose-     
dependent mechanisms of streptococcal accumulation on 
tooth surfaces according to the choice of vaccine antigen. 
Therefore, the goal of immunizing infants and young chil-
dren against colonization by mutans streptococci and hence 
diminishing the development of caries count on applying 
mucosal vaccination that would induce salivary IgA anti-
bodies without the complications of parenteral injection 
[43]. 
Information from various small-scale human trials in 
adult volunteers has shown the applicability to increase lev-
els of salivary sIgA antibodies to mutans streptococci, and 
in some cases to interfere with mutans streptococcal colo-
nization. For example, oral administration of capsules con-
taining glucosyltransferases (GTF) from S. sobrinus com-
bined with aluminum phosphate could result in an increase 
in sIgA antibody response in 14 human subjects, which 
showed interference with proportions of indigenous mutans 
streptococci/total streptococcal flora, or total cultivable flo-
ra in the oral cavity [44,45]. Intranasal immunization of 
humans with S. mutans antigens could also induce an IgA 
response in secretions [37]. However, no vaccines have 
been brought to market though we are now in the fifth dec-
ade of vaccine approaches intended to prevent or arrest 
dental caries. This is mainly because of a low ability to in-
duce and maintain protective antibodies in oral fluids [11].  
4  Salivary IgA antibodies and the protective 
responses 
Many clinical studies showed natural exposure to mutans 
streptococci results in a mucosal immune response to these 
organisms. Antibody activity to mutans streptococcal anti-
gens can be detected in both saliva and sera, which was re-
viewed by Drs. Michalek and Childers [46].  
Children often begin to synthesize serum antibodies to 
mutans streptococcal antigens mostly in the late 2nd year of 
life, when mutans streptococci begin to accumulate on pri-
mary tooth surfaces. Then serum IgG antibody levels in-
crease during childhood and remain detectable throughout 
life [40]. Prominent among the components reacting with 
IgA antibody are PAc, glucosyltransferase, and glu-
can-binding protein B. Studies that examined the associa-
tion between serum antibody to S. mutans and dental dis-
ease in young adults and older adults showed different cor-
relations between IgG antibody and their cumulative dental 
caries experience or disease levels. The various conclusions 
of these associative studies of antibodies to S. mutans in 
relation to dental caries experience reflect the complexity of 
immune response to natural exposure to mutans streptococci 
in different individuals. For detail of this subject, see review 
by Drs. Smith and Mattos-Graner [40]. 
Attempts to draw conclusions on the relationship be-
tween the levels or specificity of naturally formed salivary 
IgA antibody and dental disease in adults have also been 
problematic. Different investigations reported different rela-
tionships between levels of IgA antibody to mutans strep-
tococci and caries experience. For detail of this subject, see 
review by Drs. Smith and Taubman [38]. As the mutans 
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streptococci are usually endogenous and are present at var-
ying levels in all human mouths, and the dental disease can 
occur throughout life and may progress under diverse envi-
ronmental challenges, it is difficult to evaluate the protec-
tive efficacy of the saliva sIgA antibodies induced by natu-
ral exposure to mutans streptococci. Therefore, it is still not 
clear whether the naturally occurred sIgA against mutans 
streptococci is associated with protection against dental 
caries in man.  
Taken together, we might deduce that the naturally oc-
curred sIgA against mutans streptococci may not be strong 
enough or timely for providing protective effect against 
adhesion, colonization of the mutans streptococci and the 
following dental caries. Given that dental caries usually 
develops slowly and can occur throughout life, it may be 
anticipated that immune protection would need to be estab-
lished prior to initial colonization or accumulation and be 
similarly long-lasting throughout life.  
5  Induction of specific anti-caries salivary sIgA 
antibodies 
The concept of vaccination against dental caries has existed 
almost from the time that this disease was recognized to 
result from colonization of the teeth by acidogenic bacteria. 
Unlike most other infectious diseases, the caries specifically 
occurs on teeth surfaces bathed by external secretions in 
which the principal immunoglobulin isotype present is sIgA. 
Therefore, immunization procedures which result in the 
induction of salivary sIgA antibodies would most likely be 
effective means for inducing anti-caries immunity. Enor-
mous strides have been made in comprehending the work-
ings of the mucosal immune system by which sIgA anti-
bodies are generated in saliva and other secretions [47]. 
Furthermore, many active immunization studies demon-
strated the important anti-caries role of sIgA [43,48] though 
the relationship between the levels or specificity of naturally 
formed salivary IgA antibody and dental disease has not 
been clearly established as described above. The mecha-
nisms of action of salivary sIgA antibodies against mutans 
streptococci include interference with their sucrose-inde-      
pendent and sucrose-dependent attachment to, and accumu-
lation on, tooth surfaces, as well as possible inhibition of 
their metabolic activities [48]. Nevertheless, bacterial colo-
nization or accumulation was targeted by vaccines for inac-
tivation or blockage, rather than metabolic pathways critical 
to the survival of the microorganism. Thus, it is better to 
develop vaccines which can induce protective level of spe-
cific anti-caries salivary sIgA antibodies to prevent initial 
colonization efficiently rather than to remove cariogenic 
microorganisms from an established biofilm. 
Mucosal applications of dental caries vaccines are gener-
ally preferred for the induction of sIgA antibody in the sali-
vary compartment, since mucosal IgA immune responses 
are most efficiently induced by the administration of vac-
cines onto mucosal surfaces while injected vaccines are 
generally poor inducers of mucosal immunity [49]. Many 
investigators have shown that exposure of antigen to muco-
sally associated lymphoid tissue in the gut, nasal, bronchial, 
or rectal site can give rise to immune responses not only in 
the region of induction, but also in remote locations. 
Though the basic principle of immune protection from den-
tal caries caused by mutans streptococci has also been es-
tablished in preclinical studies, refinements to the effective 
application of this approach to humans remain. Conse-
quently, several mucosal routes have been used to induce 
protective immune responses to dental caries vaccine anti-
gens.  
Early studies with mucosally applied caries vaccines 
used the oral or intragastric route for antigen delivery. 
However, the oral route was not so ideal because the oral 
route requires antigen passage through the gut prior to up-
take in the gut-associated lymphoid tissue (GALT) and the 
acidic stomach environment diminishes the effective anti-
gen stimulus [40]. Topical applications of antigen to stimu-
late tonsil and minor salivary glands were also tried for in-
ducing mucosal immune responses in the oral cavity. Even 
remote mucosal site, for example, rectal route was investi-
gated for the ability to induce salivary IgA responses to 
mutans streptococcal antigens [33].  
6  Enhancement of specific anti-caries salivary 
sIgA antibodies by intranasal immunization with 
a safe effective mucosal adjuvant 
Different routes can lead to differential antigen presentation 
by specific dendritic cell (DC) subsets and induce differen-
tial antibody responses. In recent decade, more and more 
studies demonstrated that nasal vaccination is an effective 
regimen for the stimulation of antigen-specific protective 
immunity in both the mucosal IgA and serum IgG responses 
[50]. This route of mucosal immunization can elicit both 
humoral and cell mediated antigen-specific immune re-
sponses, and requires a much smaller dose of antigen than 
oral vaccination for the induction of antigen-specific muco-
sal and systemic immune responses. However, intranasal 
administration of vaccine antigen alone usually fails to fully 
stimulate NALT and induce mucosal and systemic immune 
responses. Thus to develop an effective NALT-targeted 
vaccine-antigen delivery system and a safe and effective 
adjuvant for intranasal administration with the vaccine an-
tigen becomes a priority for development of intranasal mu-
cosal vaccine.  
Intranasal immunization has already been used to induce 
experimental immunity to antigens associated with mutans 
streptococcal colonization and accumulation. Protection via 
this route could be demonstrated with S. mutans PAc, GtfB, 
GbpB or GbpB-derived peptides [28,33], and even fimbrial 
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preparations from S. mutans [51], using antigen alone or in 
combination with mucosal adjuvants. Specific saliva sIgA 
responses against S. mutans could also be elicited by in-
tranasal immunization of pCIA-P/bupivacaine DNA com-
plex [7,8]. The Fan group also tried to identify compounds 
and conditions that would increase antibody levels which 
could also improve the protective effect for anti-caries DNA 
vaccines since DNA vaccines are relatively weak immuno-
gens [11]. This group demonstrated chitosan could increase 
salivary IgA antibody responses as adjuvants to a DNA 
vaccine of pGJA-P/VAX [12]. We sought to further en-
hance salivary IgA and serum IgG antibody responses by 
including Salmonella-derived flagellin protein at the time of 
pGJA-P/VAX administration [11,20]. We found that re-
combinant flagellin protein as a mucosal adjuvant for an-
ti-caries DNA vaccine pGJA-P/VAX via intranasal immun-
ization can increase serum PAc-specific IgG and saliva 
PAc-specific IgA antibody responses as compared with 
pGJA-P/VAX alone and significantly decrease the coloni-
zation of S. mutans on rat teeth. More importantly, flagellin 
protein as a mucosal adjuvant promoted the ability of 
pGJA-P/VAX to reduce caries lesions, providing effective 
protection against dental caries. It is demonstrated that re-
combinant flagellin protein as a mucosal adjuvant for in-
tranasal caries DNA vaccine enhanced saliva IgA response 
and conferred better protection against caries [20]. 
Investigators have long sought to enhance mucosal IgA 
antibody responses by using different delivery systems such 
as liposomes, PLGA microparticles, ISCOMs or bioactive 
components as mucosal adjuvant such as Cholera toxin 
(CT), heat-labile enterotoxins (HLT) from Vibrio cholera 
(LT-I) or Escherichia coli (LT- II) [33]. These bioactive 
components can induce vigorous mucosal (and systemic) 
immune responses when used as adjuvants for protein anti-
gens. However, their inherent toxicity precludes the use of 
such holotoxins in human vaccines, though work continues 
to identify safe HLT subcomponents which retain signifi-
cant immunomodulatory characteristics that can be used at 
the preferred intranasal site [10,11].  
The field of vaccine adjuvants has been rapidly evolving 
since the discovery of the Toll-like receptor (TLR) family 
of pattern recognition molecules. The TLRs are mem-
brane-bound receptors responsible for recognizing invading 
microorganisms by pathogen-associated molecular patterns 
(PAMPs). Binding of TLRs to PAMPs signals presence of 
microbial pathogens and triggers series of events that acti-
vate immune response. Thus, TLR ligands that mimic 
PAMPs and activate immune cells via TLRs are being de-
veloped for vaccine adjuvants to aid the generation of ro-
bust and long-lasting adaptive immune responses [52]. The 
principal ligands for TLRs 1, 2, 3, 5, 6, 7, and 9 were de-
termined by gene targeting as early as between 1999 and 
2003 [53]. A number of these ligands are now in clinical or 
late preclinical stages of development for multiple applica-
tions including vaccine adjuvants [54]. Among them, bacte-
ria flagellin is very unique due to its protein property, which 
is recognized by cell surface TLR5, the only protein-     
binding TLR that is conserved in vertebrates from fish to 
mammals. The flagellin molecule, consisting of conserved 
domains at the N terminus and C terminus and a middle 
hypervariable domain, can also be recognized by the cyto-
solic NLRC4 inflammasome receptor NAIP5 [55,56], 
though the contribution of this cytosolic pathway to the ad-
juvant activity of flagellin needs to be further defined [57]. 
In view of the substantial potency of flagellin as a potent 
activator of a broad range of cell types involved in innate 
and adaptive immunity, the potential of this fascinating 
protein seems to be almost unlimited for many applications 
[58]. 
7  Enhancement of salivary sIgA antibodies and 
anti-caries protection by intranasal immuniza-
tion with flagellin-PAc fusion protein 
The finding that flagellin from many bacteria species was a 
ligand for TLR5 further suggested its potential as an adju-
vant [59]. Thereafter, an increasing number of studies have 
demonstrated the effectiveness and advantages of flagellin 
as a novel attractive adjuvant [58]. Furthermore, flagellin 
has also been proven to be an effective mucosal adjuvant in 
many vaccines against pathogens like Yersinia pestis, West 
Nile virus [15,16]. We have also demonstrated that recom-
binant FliC protein derived from Salmonella is an excellent 
mucosal adjuvant for enhancing local IgA responses [60].  
Flagellin has a number of advantages for development of 
a promising adjuvant for use in human vaccines [58]. The 
most attractive advantage is the plasticity of flagellin for 
generation of fusion proteins of recombinant vaccine anti-
gens and flagellin [61]. The fusion strategy can be achieved 
by inserting vaccine target antigen at the N-terminus or 
C-terminus or within the hypervariable region of the flagel-
lin. A number of vaccine candidates with this strategy have 
reached early stage clinical studies, and this represents one 
of the most promising new directions in vaccine develop-
ment [13,14,17–19]. 
Based on the great capacity of flagellin to induce humor-
al and cellular immune responses, as well as mucosal im-
mune response against foreign antigens, we explored the 
use of this molecule for the generation of fusion proteins 
containing caries vaccine antigens. We tried to insert the 
A-P fragment of PAc from S. mutans (rPAc) at the 
C-terminus of flagellin derived from E. coli (designated as 
KF) to produce a single recombinant protein (KF-rPAc) in 
the E. coli expression system. It was demonstrated that 
KF-rPAc could promote significant higher rPAc-specific 
antibodies in serum as well as in saliva compared with the 
rPAc alone or mixture of rPAc and KF (KF+rPAc). Previ-
ous studies usually used at least 50 μg dosage of PAc pro-
tein, chimeric protein SBR-GLU, or CTB-PAc coupled 
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immunogen for inducing detectable mucosal immune re-
sponses or protective salivary IgA antibody against S. mu-
tans infection in rats [62,63]. By flagellin-PAc fusion strat-
egy, 4.2 μg of KF-rPAc, which is equivalent to 2.5 μg rPAc, 
could induce high levels of immune responses; and 8.5 μg 
KF-rPAc could induce significantly elevated antibody re-
sponses and confer effective reduction of dental caries in 
rats. This fusion strategy of rPAc antigen with flagellin sig-
nificantly reduced vaccine dosage. The most impressive 
result is that intranasal immunization of 8.5 μg KF-rPAc 
achieved 64.2% reduction of dental caries in rats [21]. This 
demonstrated that flagellin and PAc fusion strategy is prom-
ising for anti-caries vaccine development, and KF-rPAc 
could be a good candidate of anti-caries mucosal vaccine.  
However, the very potent antigenicity of flagellin itself 
led to a concern that immunity to flagellin might affect the 
potency of this molecule and induce possible side effects 
when used as a mucosal adjuvant [64], although there were 
reports that prior immunity to flagellin does not impair its 
adjuvant activity and does not lead to serious systemic ef-
fects [15]. We tried to replace the main antigenicity region 
domains D2 and D3 of flagellin with rPAc and successfully 
obtained a soluble KFD-rPAc recombinant protein. As we 
expected, KFD-rPAc reduced by more than 95% of the im-
munogenicity against full-length flagellin KF protein [65]. 
Surprisingly, this replacement of domains D2 and D3 in 
flagellin could induce high IgA-biased antibody responses 
at different mucosal sites and far fewer flagellin-induced 
systemic inflammatory responses [65]. The propensity to 
produce IgA-biased responses in mucosal sites especially in 
oral cavity is important and promising for caries mucosal 
vaccines. 
8  Development of a nasal-spray or nasal-drop 
anti-caries vaccine for human use 
Although the requirement for the physical linking of flagellin 
to the antigen is still a matter of debate, our observation 
showed that the replacement of the whole hypervariable 
region D2 and D3 of flagellin with vaccine antigen promotes 
mucosal IgA production and attenuates flagellin-induced 
inflammatory response after intranasal immunization [65]. 
The reason why the whole hypervariable region D2 and D3 
of flagellin with vaccine antigen has propensity to produce 
IgA-biased responses in mucosal sites is intriguing and 
worth further exploration. The practical use of this strategy 
is essential for development of an effective and safe anti-     
caries vaccines. To our knowledge, the KF-rPAc [21] and 
KFD-rPAc (unpublished data) are two good prototypes of 
anti-caries intranasal vaccines, which are easy for recombi-
nant protein production in E. coli expression system at a 
large scale and low product cost for commercial use. The 
use of recombinant fusion flagellins containing PAc insert-
ed into hypervariable region may be a simple and inexpen-
sive way to enhance antigenicity of PAc for nasal immun-
ization. The fact that recombinant flagellins have reached 
Phase I/II clinical trials should accelerate further studies in 
this direction [19,66]. 
Considering the closer anatomical relationship to the oral 
cavity and the convenience for vaccine administration, in-
tranasal immunization is likely to be the first choice for 
caries vaccine, which targets the nasal-associated lymphoid 
tissue (NALT). Caries vaccines can be administered in a 
nasal drop or nasal spray rather than in a hypodermic needle. 
Kids may choose nasal immunization more gladly over the 
formidable needles that deliver other vaccines. Intranasal 
caries vaccines, directed to key components of mutans 
streptococcal colonization and enhanced by safe and effec-
tive mucosal adjuvants and optimal delivery vehicles, are 
likely to be forthcoming [11]. However, some other ele-
ments should also be taken into account.  
As dental caries usually develops slowly and occurs 
throughout life, immune protection would need to be 
long-lasting. Thus, the duration and anamnestic recall of 
salivary antibody responses are important factors. It is now 
clear that mucosal vaccination can induce both memory 
IgA+ and memory IgG+ B cells after oral, intranasal and 
intravaginal vaccinations [67]. Studies showed protection 
against infection induced by mucosal vaccines can last for 
several years, even though intestinal IgA responses vanish 
after 6–9 months [68–70]. For caries vaccines, the duration 
of salivary IgA responses induced by mucosal immuniza-
tion need to be explored further. However, the longer dura-
tion of salivary IgA responses and related protection can be 
achieved by a renewed exposure to the mutans streptococcal 
or boost immunization to elicit a rapid recall response and 
thereby to sustain the capacity for preventing infection 
[68,71]. 
Given that oral colonization with mutans streptococci 
mainly occurs during a ‘window of infectivity’ at around 
two years of age after primary teeth begin to erupt, it would 
be necessary to immunize infants or young children in order 
to provide immune protection prior to initial colonization 
with mutans streptococci [43]. For infants or young children, 
the safety of the immunization is the first priority. KF-rPAc 
and KFD-rPAc are good and safe choice for a preventive 
caries vaccine for infants and young children, in which the 
salivary IgA responses only inhibited oral colonization and 
biofilm formation of mutans streptococci but did not disturb 
growth of oral flora (unpublished data). Another alternative 
safe way for infants is to immunize young mothers intrana-
sally for reducing their oral load of mutans streptococci and 
thereby diminishing the probability and extent of transmis-
sion to their infants. On the other hand, this way will induce 
the generation of antibodies to mutans streptococci in 
breast-milk and passively transfer IgA antibodies to protect 
infants at earlier stage through breast-feeding, though the 
protection effect needs to be demonstrated further [43].  
Due to the current high caries prevalence rate all over the 
412 Yan H M.   Sci China Life Sci   May (2013) Vol.56 No.5 
world, for juvenile and adults who have been already in-
fected by mutans streptococci, a therapeutic anti-caries vac-
cine is an urgent need. To be able to clear micro-organisms 
from the oral cavity by antibody-mediated aggregation after 
colonization and accumulation of mutans streptococci, mul-
tiple specific antibodies to block the glucan-binding do-
mains of GBPs and GTF, or inactivate GTF enzymes re-
sponsible for glucan formation might be also needed for 
enhancement of the antimicrobial activity by synergism. At 
present, there is no one-fit-all vaccine for any disease. 
Clearly, several possible dental caries vaccine approaches 
may have application in clinical trials. Finally, clinical trials 
of immunologically superior dental caries vaccine formula-
tions will determine their usefulness for public health ap-
plications ultimately.  
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